English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16812/19099 (88%)
Visitors : 6889044      Online Users : 960
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31038


    標題: Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis
    作者: Liao, Kuang-Ming
    Chao, Tung-Bo
    Tian, Yu-Feng
    Lin, Ching-Yih
    Lee, Sung-Wei
    Chuang, Hua-Ying
    Chan, Ti-Chun
    Chen, Tzu-Ju
    Hsing, Chung-Hsi
    Sheu, Ming-Jen
    Li, Chien-Feng
    貢獻者: Chi Mei Med Ctr, Dept Internal Med
    Yuans Gen Hosp, Dept Colorectal Surg
    Meiho Univ, Dept Hlth Business Adm
    Chi Mei Med Ctr, Div Gen Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Internal Med
    Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management
    Chi Mei Med Ctr, Dept Radiat Oncol
    Chi Mei Med Ctr, Dept Pathol
    Chi Mei Med Ctr, Dept Anesthesiol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    關鍵字: PSAT1
    Nasopharyngeal carcinoma
    prognosis
    trials
    日期: 2016
    上傳時間: 2018-01-18 11:40:22 (UTC+8)
    出版者: Ivyspring Int Publ
    摘要: Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR=2.856, 95% CI 1.599 to 5.101), DMFS (HR=3.305, 95% CI 1.720 to 6.347), LRFS (HR=2.834, 95% CI 1.376 to 5.835), and OS HR=2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.
    關聯: Journal of Cancer, v.7 n.9, pp.1088-1094
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    31038.pdf742KbAdobe PDF32View/Open
    index.html0KbHTML81View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback